Effect of enhanced external counterpulsation treatment on renal function in cardiac patients

BMC Nephrology

Table 3 Change of Cys C and GFR after EECP treatment (n = 30)

Characteristics	Median (IQR)
Characteristics	Baseline	End of 35^thsession	Follow-up
*Estimated GFR*
GFR <60 mL/min/1.73 m² (n = 12)	n = 12	n = 9	n = 12
Cystatin C (mg/L)	1.55	1.44	1.4
	(1.26-1.85)	(1.2-1.59)	(1.14-1.65)
p-value		0.173 ^a	0.004 ^b **
GFR (mL/min per 1.73 m²)	43.59	46.11	47.52
	(39.1-53.29)	(42.06-47.26)	(41.1-55.76)
p-value		0.374 ^a	0.003 ^b **
GFR ≥60 mL/min/1.73 m² (n = 18)	n = 18	n = 18	n = 18
Cystatin C (mg/L)	0.83	0.82	0.8
	(0.73-0.89)	(0.72-0.91)	(0.63-0.92)
p-value		0.931 ^a	0.052 ^b
GFR (mL/min per 1.73 m²)	86.05	92.34	88.81
	(75.16-103.3)	(83.46-105.38)	(81.22-109.79)
p-value		0.157 ^a	0.124 ^b
*NT-proBNP*
NT-proBNP ≤125 pg/mL (n = 9)	n = 9	n = 9	n = 9
Cystatin C (mg/L)	0.78	0.82	0.81
	(0.76-0.87)	(0.72-0.87)	(0.77-0.87)
p-value		0.906 ^a	0.553 ^b
GFR (mL/min per 1.73 m²)	86.69	88.75	83.11
	(85.28-92.84)	(83.46-105.23)	(81.42-96.54)
p-value		0.374 ^a	0.767 ^b
NT-proBNP >125 pg/mL (n = 20)	n = 20	n = 17	n = 20
Cystatin C (mg/L)	1.26	1.16	1.14
	(0.94-1.68)	(0.84-1.53)	(0.88-1.51)
p-value		0.523 ^a	0.001 ^b**
GFR (mL/min per 1.73 m²)	59.43	57.66	62.26
	(43.31-74.47)	(46.11-91.46)	(46.97-83.18)
p-value		0.246 ^a	0.001 ^b**
*NT-proBNP decline >30% from baseline (n = 10 )*	n = 10	n = 9	n = 10
Cystatin C (mg/L)	1.01	1.00	0.97
	(0.81-1.31)	(0.77-1.2)	(0.69-1.2)
p-value		0.594 ^a	0.017 ^b*
GFR (mL/min per 1.73 m²)	65.53	66.87	66.46
	(43.68-79.98)	(47.26-93.98)	(49.02-91.85)
p-value		0.214 ^a	0.051 ^b

Values are Median (25^th-75^th percentile). p- value was calculated with the use of Wilcoxon signed ranks test, ^a End of 35^th session versus baseline; ^b Last follow-up versus baseline.
(*) indicated statistically significant p-value less than 0.05; (**) indicated statistically significant p-value less than 0.01.

ISSN: 1471-2369